The use of a new oral antiviral drug molnupiravir in the treatment of COVID-19 from a safety perspective
Molnupiravir is an antiviral drug with a broad spectrum of activity against RNA viruses. The safety of molnupiravir in clinical trials with COVID-19 was analyzed. In a Phase I study (NCT04392219), molnupiravir was well tolerated at doses of 50 to 800 mg twice daily for 5.5 days and at single doses u...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Izdatelstvo OKI,
2022-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|